Schonfeld Strategic Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25,000	Closed	-$1.47M	–	2534
2023 Q4	$1.47M	Buy	+25,000	New	+$1.41M	0.01%	906

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Schonfeld Strategic Advisors's MRTX Position: Q1 2024 in Review

Schonfeld Strategic Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,161 shares — an estimated $68.2K sold.

Schonfeld Strategic Advisors first reported a position in MRTX in Q4 2017 and held it in 22 quarters. The position peaked at $22.7M in Q2 2019. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Schonfeld Strategic Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Schonfeld Strategic Advisors sold 1,161 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $68.2K.
Schonfeld Strategic Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 22 quarters.
Schonfeld Strategic Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $22.7M in Q2 2019.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2024, filed 15 May 2024.